Alternatively, sodium-glucose cotransporter-2 (SGLT2) inhibitors may offer multiple potential benefits in ADPKD by targeting various pathophysiological pathways. This evidence concerns the gene SLC5A2 and autosomal dominant polycystic kidney disease.